Post-Polycythemia Vera Myelofibrosis (PPV-MF) is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Post-Polycythemia Vera Myelofibrosis (PPV-MF) have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Post-Polycythemia Vera Myelofibrosis (PPV-MF) compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) overview
Post-polycythemia vera myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, headaches, lack of concentration, and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant, and medications.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Post-Polycythemia Vera Myelofibrosis (PPV-MF), buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
